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Dual PI3K/ERK inhibition induces 
necroptotic cell death of Hodgkin 
Lymphoma cells through IER3 
downregulation
Silvia Laura Locatelli1, Giuseppa Careddu1, Giuliano Giuseppe Stirparo1, Luca Castagna1, 
Armando Santoro1,2 & Carmelo Carlo-Stella1,3
PI3K/AKT and RAF/MEK/ERK pathways are constitutively activated in Hodgkin lymphoma (HL) 
patients, thus representing attractive therapeutic targets. Here we report that the PI3K/ERK dual 
inhibitor AEZS-136 induced significant cell proliferation inhibition in L-540, SUP-HD1, KM-H2 and 
L-428 HL cell lines, but a significant increase in necroptotic cell death was observed only in two out of 
four cell lines (L-540 and SUP-HD1). In these cells, AEZS-136-induced necroptosis was associated with 
mitochondrial dysfunction and reactive oxygen species (ROS) production. JNK was activated by AEZS-
136, and AEZS-136-induced necroptosis was blocked by the necroptosis inhibitor necrostatin-1 or the 
JNK inhibitor SP600125, suggesting that JNK activation is required to trigger necroptosis following 
dual PI3K/ERK inhibition. Gene expression analysis indicated that the effects of AEZS-136 were 
associated with the modulation of cell cycle and cell death pathways. In the cell death-resistant cell 
lines, AEZS-136 induced the expression of immediate early response 3 (IER3) both in vitro and in vivo. 
Silencing of IER3 restored sensitivity to AEZS-136-induced necroptosis. Furthermore, xenograft studies 
demonstrated a 70% inhibition of tumor growth and a 10-fold increase in tumor necrosis in AEZS-136-
treated animals. Together, these data suggest that dual PI3K/ERK inhibition might be an effective 
approach for improving therapeutic outcomes in HL.
Approximately 9,300 new cases of Hodgkin lymphoma (HL) and 1,200 resulting deaths are estimated to occur 
each year in the United States1. Combination chemotherapy with or without radiotherapy cures approximately 
80% of advanced-stage HL cases2. However, 20–30% of patients are initially refractory to chemotherapy or expe-
rience early or late disease relapse and are not cured using modern treatments3. Second-line high-dose salvage 
chemotherapy (HDC) and autologous stem cell transplantation have established roles in the management of 
refractory/relapsed HL and lead to long-term complete remission in approximately 50% of relapsed patients and 
a minority of refractory patients4. Refractory/resistant HL patients represent an unmet medical need requiring 
the development of effective salvage regimens5.
Several molecularly targeted agents, including histone deacetylase (HDAC) inhibitors6, mammalian target 
of rapamycin (mTOR) inhibitors7, and immunomodulatory drugs8, have been tested in phase I/II trials. Used 
as single agents, these molecules have a limited efficacy9. More recently, the alkylating agent bendamustine10, 
the anti-CD30 antibody-drug conjugate brentuximab vedotin11,12, and the anti-programmed cell death protein-1 
(PD-1) antibody nivolumab13,14 have demonstrated extraordinary efficacy. However, limited evidence has been 
provided for long-term disease control using these agents, suggesting that either combination therapy or a single 
agent with multitargeting capacity is required15.
Aberrant regulation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway has frequently been observed 
in Hodgkin Reed-Sternberg (HRS) cells,16,17 suggesting that PI3K is an attractive therapeutic target18–20. Cancer 
cells frequently exhibit increased oxidative stress and are likely to be more sensitive to the damage promoted by 
reactive oxygen species (ROS)21. We recently demonstrated that upon HDAC and MEK/ERK inhibition, ROS 
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production is critically involved in lymphoma cell death via necroptosis22. Additionally, several studies have 
implicated MAPKs, PI3K/AKT, and NF-kB in the regulation of cell death23.
To investigate the therapeutic potential of PI3K and ERK dual inhibition, we used AEZS-136 [kindly provided 
by Æterna Zentaris (Frankfurt, Germany, EU)] in preclinical models of HL. AEZS-136 concurrently inhibits 
Erk1/2 and Pl3K by an ATP competitive mode of action. AEZS-136 is a dual Pl3K/Erk inhibitor based on a pyri-
dopyrazine scaffold. The anti-proliferative efficacy of AEZS-136 was evaluated in more than 40 human tumor cell 
lines and physio-chemical as well as in-vitro ADMET properties were widely assessed. Furthermore, the in vivo 
pharmacokinetics and anti-tumor efficacy was explored. AEZS-136 was well tolerated and showed dose depend-
ent inhibition of human colon tumor growth of up to 72% in a Hct116 mouse model (I. Seipelt, Aeterna Zentaris, 
personal communication)24.
We report herein that AEZS-136 potently induced the dephosphorylation of MAPK and PI3K/AKT pathway 
components, leading to caspase-independent necroptosis. Besides downregulating the phosphorylated form of 
the anti-apoptotic proteins Mcl-1 and ERK1/2, AEZS-136 strongly increased JNK expression. These activities 
were dependent on potent, early, and time-dependent ROS generation and translated into significant antitumor 
activity in vivo. Immediate early response 3 (IER3) was identified as a key signaling molecule that mediated resist-
ance to AEZS-136-induced oxidative death.
Results
AEZS-136 modulates the phosphorylation of MAPK and PI3K/AKT pathway constituents. 
Preliminary experiments involving a panel of HL cell lines (L-540, SUP-HD1, KM-H2, L-428, HDLM-2; 
Supplementary Fig. S1) and lymph node biopsies from HL patients (n = 10; Supplementary Fig. S2) demonstrated 
constitutively high phosphorylation levels of ERK1/2 and AKT with no differences between chemosensitive and 
chemoresistant patients, suggesting that combined ERK1/2 and AKT inhibition with AEZS-136 might have 
therapeutic relevance. Time-course experiments showed that ERK1/2 phosphorylation was downregulated in a 
time-dependent manner in L-540 and SUP-HD1 cells, whereas it was upregulated although at different degrees in 
KM-H2 and L-428 cells (Fig. 1a). Similarly, the phosphorylation levels of PI3K and its downstream targets (AKT, 
S6, and 4EBP1) were inhibited in all HL cell lines (Fig. 1a). Since the PI3K/Akt and Raf/MEK/ERK pathways 
regulate members of the Bcl-2 family of proteins, such as Mcl-125, we examined whether AEZS-136 would affect 
Mcl-1 expression. AEZS-136 significantly downregulated Mcl-1 expression in the L-540 and SUP-HD1 cells, but 
not in the KM-H2 or L-428 cells (Fig. 1a). Dose-dependent experiments confirmed that increasing concentra-
tions of AEZS-136 (1.25 to 20 μ M) inhibited AKT phosphorilation in all of the tested cell lines, with L-540 and 
SUP-HD1 being more responsive to AEZS-136 than the KM-H2 and L-428 cells (Fig. 1b). However, AEZS-136 
dose-dependently reduced pERK1/2 expression in L-540 and SUP-HD1 cells, whereas only high concentration of 
AEZS-136 (20 μ M) was able to reduce ERK1/2 activation in KM-H2 and L-428 cells.
In vitro antiproliferative activity of AEZS-136. Incubating L-540 and SUP-HD1 cell lines for up to 
72 hours with increasing doses of AEZS-136 (2.5–10 μ M) resulted in a significant dose- and time-dependent 
decrease in cell proliferation (Fig. 1c). For both cell lines, the peak of the cytostatic effect was detected upon incu-
bation with 10 μ M of AEZS-136 for 72 hours, when the cell proliferation of L-540 and SUP-HD1 cells was signifi-
cantly (P ≤ 0.0001) decreased to 64 ± 4% and 59 ± 1% (mean ± SEM), respectively. Under the same experimental 
conditions, the cell proliferation of both KM-H2 and L-428 cells was modestly affected by AEZS-136. Cell cycle 
analysis of L-540 and SUP-HD1 cells exposed to AEZS-136 (10 μ M, 48 hours) resulted in a significant reduction 
of cells in S phase of 63% and 49%, respectively, compared with vehicle-treated controls and significant G0/G1 
cell cycle arrest (Fig. 1d) that was associated with the induction of p21 (Fig. 1e). A similar trend was detected in 
the KM-H2 and L-428 cells.
Mechanisms of AEZS-136-induced cell death. AEZS-136 treatment resulted in a significant time- and 
dose-dependent increase in cell death in L-540 and SUP-HD1 cells but not in KM-H2 or L-428 cells (Fig. 1f). 
Whereas modest effects were detected upon exposure to 2.5 or 5 μ M AEZS-136, incubation with 10 μ M AEZS-136 
for 72 hours significantly increased cell death over vehicle-treated controls in both the L-540 (52 ± 4 vs. 19 ± 3%, 
P ≤ 0.0001) and SUP-HD1 (40 ± 1% vs. 16 ± 1%) cell lines (P ≤ 0.0001; Fig. 1f, Supplementary Fig. S3).
Previous studies investigating the mechanism(s) of MAPK or AKT inhibitor-induced cell death in NHL and 
HL cell lines have demonstrated the induction of different death pathways involving both caspase-dependent 
and caspase-independent mechanisms26, ROS generation27, and JNK activation28. AEZS-136-induced cell death 
in responsive cell lines was not associated with caspase-3 processing or PARP cleavage (Supplementary Fig. S4), 
and it was not reversed by the pan-caspase inhibitor Z-VAD-FMK (Supplementary Fig. S4), strongly suggesting 
that AEZS-136 acted via a caspase-independent pathway. Additionally, AEZS-136 treatment led to marked mito-
chondrial depolarization (up to 40%), which was detected in the cell death-susceptible cells even in the presence 
of Z-VAD-FMK (Supplementary Fig. S4).
AEZS-136-induced cell death is associated with ROS generation. To further investigate the molec-
ular mechanisms by which AEZS-136 triggered cell death we chose the most and the least cell death-responsive, 
i.e., L-540 and L-428 cell lines. Upon AEZS-136 exposure, the cell death-susceptible L-540 cells, but not L-428 
cells, showed a marked (up to 90%) time-dependent increase in ROS production (Fig. 2a), which was prevented 
by the ROS inhibitor YCG063 (Fig. 2b). Since ROS act as secondary messengers in the necroptotic pathway27,29, 
we analyzed the effects of YCG063 and necrostatin-1 on cells exposed to AEZS-136. The exposure of L540 cells to 
AEZS-136, in combination with either YCG063 or necrostatin-1, prevented ROS generation and mitochondrial 
membrane depolarization (Fig. 2c) and reduced cell death to baseline levels (Fig. 2d). Overall, these results indi-
cated that ROS generation are involved in mitochondrial perturbation and necroptotic cell death.
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Figure 1. AEZS-136 treatment affects the PI3K/AKT and MAPK pathways, reduces cell proliferation, 
and increases cell death. (a) Immunoblots of extracts from HL cells treated with AEZS-136 (10 μ M) or 
DMSO vehicle for 0.5, 1, or 2 hours. Equal protein loading was confirmed by immunoblotting for β -actin. The 
experiments were repeated twice with similar results. Representative blots are shown. (b) Dose-dependent 
effect of AEZS-136 (1.25–20 μ M) on phosphorylated and total AKT and ERK after exposure to AEZS-136 or 
DMSO vehicle for 2 hours in HL cells. (c) HL cells were exposed to 2.5 μ M (green), 5 μ M (blue), or 10 μ M (red) 
AEZS-136 for 24, 48, or 72 hours, after which, the cell proliferation was assessed as described in the Methods 
section. The mean (±SEM) values refer to three independent experiments. *P ≤ 0.0001, ≠ P ≤ 0.001, °P ≤ 0.01, 
and ≈ P ≤ 0.05 compared with vehicle-treated cells. (d) Cell cycle analysis of AEZS-136 (10 μ M)-treated L-540, 
SUP-HD1, KM-H2, and L-428 cells or vehicle-treated controls after 48 hours. Flow cytometry was performed to 
measure the cell cycle distribution of treated cells compared with untreated controls. The mean (± SEM) values 
refer to three independent experiments. *P ≤ 0.05 and **P ≤ 0.01 compared with vehicle-treated cells.  
(e) Immunoblots of extracts from HL cells treated with AEZS-136 (10 μ M) or vehicle-treated controls for 
48 hours. Equal protein loading was confirmed by immunoblotting for β -actin. The experiments were repeated 
twice with similar results. Representative blots are shown. (f) HL cells were exposed to 2.5 μ M (green), 5 μ M 
(blue), and 10 μ M (red) AEZS-136 for 24, 48, and 72 hours, after which, the percentage of dead cells (Annexin 
V+ /PI+ plus Annexin V− /PI+ ) was obtained as described in the Methods section. The mean (± SEM) values 
correspond to three independent experiments. *P ≤ 0.0001, ≠ P ≤ 0.001, °P ≤ 0.01, and ≈ P ≤ 0.05 compared 
with the vehicle-treated control cells.
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Figure 2. Cell death induced by AEZS-136 correlates with JNK-dependent ROS production. (a) Live cell 
imaging of ROS production in AEZS-136 (10 μ M)-treated L-540 and L-428 cells. Representative image captured 
120 minutes after drug treatment are shown. Objective lens, 1.0 NA oil objective; original magnification, 40x. 
(b) L-540 cells were pre-labeled with H2DCFDA and then treated with the ROS inhibitor YCG063 (20 μ M). 
After 5 min, the indicated samples were stimulated with 10 μ M AEZS-136 or DMSO vehicle. ROS inhibition 
was quantified using Cell R 5 software. Representative image captured 30 min after drug treatment are shown. 
Objective lens, 1.0 NA oil objective; original magnification, 40x. (c,d) L-540 cells were treated with or without 
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JNK activation is involved in AEZS-136-induced ROS generation. JNK, a member of the MAPK 
family, plays an essential role in cell death30 and interacts with ROS through a JNK-ROS feedback loop that 
is involved in ROS-mediated cell death31. To investigate the role of JNK in AEZS-136-induced necroptosis via 
ROS, experiments were performed using the specific JNK inhibitor SP600125, the ROS inhibitor YCG063, and 
necrostatin-1. AEZS-136 upregulated p-JNK in L-540 and SUP-HD1 cells but not in KM-H2 and L-428 cells 
(Fig. 2e), a phenomenon that was counteracted by SP600125 (Fig. 2f). Flow cytometry showed that SP600125 pre-
vented AEZS-136-induced mitochondrial depolarization, necroptotic cell death, and ROS generation (Fig. 2g), 
suggesting JNK-dependent ROS production. Moreover, necrostatin-1 and YCG063 inhibited the expression of 
p-JNK (Fig. 2f), supporting the existence of a JNK-ROS loop in AEZS-136-induced HL necroptosis (Fig. 2h).
AEZS-136 modulates gene expression. To gain further insights into the molecular mechanism(s) of 
action of AEZS-136, the gene expression profiles of vehicle-treated controls and AEZS-136-treated cell lines were 
analyzed. Supervised hierarchical clustering of HL cell lines demonstrated that AEZS-136 exposure resulted in 
early effects, as shown by the significantly modulated genes detected after a 2-hour incubation (Supplementary 
Fig. S5), with a substantial increase in significantly modulated genes detected after 24 hours (Supplementary 
Fig. S5). A Venn diagram showed that the majority of the 2-hour modulated genes remained modulated at the 
24-hour time point (L-540 and L-428 cell lines), and almost all genes were concordantly modulated (upregulated 
or downregulated) at both time points (Supplementary Fig. S5). These changes were validated via qRT-PCR using 
selected genes (Supplementary Fig. S6). Biological processes significantly involved both at early (2 hours) and 
late (24 hours) time points included signal transduction and kinase activity, cell cycle, and cell death, as well as 
transcription and translation (Supplementary Fig. S7, Supplementary Table S1).
To explain the intrinsic resistance to AEZS-136-induced necroptotic cell death observed in the KM-H2 and 
L-428 cell lines, we used data from the 24-hour time point to perform a stringent gene ontology analysis with 
differentially expressed genes. By comparing gene ontology results, we identified specific and common biolog-
ical processes involved in AEZS-136 sensitivity or resistance (Fig. 3a, Supplementary Table S2). These data led 
to the identification of a subset of genes involved in cell death and cell proliferation (Supplementary Table S2). 
Genes involved in the “cell cycle” were specifically enriched in L-540 and SUP-HD1 cells (Fig. 3a, orange nodes), 
whereas genes involved in the “cell cycle” and “regulation of cell death” were enriched in all HL cells (Fig. 3a, 
yellow nodes). Interestingly, negative “regulation of cell death, programmed cell death and apoptosis” were spe-
cifically enriched in KM-H2 and L-428 cells (Supplementary Table S3 and Fig. 3a, blue nodes), suggesting a 
potential role of these processes in resistance to AEZS-136 treatment. Considering only the genes enriched in 
the blue nodes (156 genes, Supplementary Table S3 and Fig. 3a), we selected genes expressed in at least three 
cell lines (40 genes, Fig. 3b) and subsequently focused on genes showing an opposite regulation between the cell 
death-resistant (KM-H2 and L-428) and cell death-sensitive (L-540 and SUP-HD1) cell lines (the absence of 
regulation was not considered). Interestingly, the immediate early response 3 (IER3) gene was the only gene that 
fulfilled our filtering criteria. IER3 was significantly upregulated by AEZS-136 in the cell death-resistant cell lines, 
whereas it was downregulated in the AEZS-136-sensitive L-540 and SUP-HD1 cell lines (Fig. 3b), regardless of 
the similar IER3 basal expression in all HL cell lines (Fig. 3c).
Next, we investigated the impact of IER3 on cell survival in the AEZS-136-resistant cell lines. We depleted 
KM-H2 and L-428 cells in IER3 using two specific siRNAs (Fig. 4a, Supplementary Fig. S8), and cell death 
(Fig. 4b) and ROS production (Fig. 4c) were monitored after AEZS-136 treatment. IER3 depletion in AEZS-
136-treated cells resulted in massive increase in cell death (Fig. 4b) and ROS production (Fig. 4c), suggesting that 
IER3 is a cell death-protective protein against AEZS-136 treatment. Finally, to confirm that IER3 is involved in the 
resistance to AEZS-136 treatment, a genetic rescue was designed. AEZS-136-sensitive L-540 cells transduced with 
lentivirus designed to overexpress IER3 (Supplementary Fig. S9) were treated with AEZS-136, and cell death was 
monitored. No cell death prevention was observed with the Scrambled vector, whereas a 50% cell death reduction 
was observed in LV IER3-transduced L-540 cells (Supplementary Fig. S9). Together, these data strongly suggest 
that IER3 upregulation mediates resistance to AEZS-136 (Fig. 4d).
Since we have shown that AEZS-136 induced upregulation of both IER3 and phospho-ERK expression in the 
AEZS-136-resistant cell lines, we investigated the IER3/ERK1/2 relationships. When AEZS-136-treated KM-H2 
and L-428 cells were exposed to the ERK1/2 siRNA, both ERK1/2 (Supplementary Fig. S10) and IER3 levels were 
the ROS inhibitor YCG063 (20 μ M) or necrostatin-1 (60 μ M). After 1 hour, the appropriate samples were 
stimulated with 10 μ M AEZS-136 or DMSO vehicle for 48 hours and (c) ROS generation or mitochondrial 
membrane depolarization were assessed. The experiments were repeated twice with similar results. 
Representative dot plots are shown. (d) Cell death was measured via Annexin-V/PI double-staining. The mean 
(± SEM) values represent three independent experiments. *P ≤ 0.0001 compared with the cells treated with 
AEZS-136 and AEZS-136 plus YCG063 or necrostatin-1. Vehicle-treated controls are shown. (e) Western blot 
analysis of extracts from HL cells treated with 10 μ M AEZS-136 or DMSO vehicle for the indicated periods. 
Total levels of JNK and β -actin are shown. (f) L-540 cells were treated with or without the ROS inhibitor 
YCG063 (20 μ M), necrostatin-1 (60 μ M), or the JNK inhibitor SP600125 (12.5 μ M). After 1 hour, the indicated 
samples were stimulated with 10 μ M AEZS-136 or DMSO vehicle for 15 min. JNK expression was measured 
via flow cytometry. (g) L-540 cells were incubated for 1 hour in the presence or absence of the JNK inhibitor 
SP600125 (12.5 μ M). Following exposure to AEZS-136 (10 μ M, 24 hours) or DMSO vehicle, mitochondrial 
membrane depolarization, cell death, and ROS generation were analyzed via flow cytometry. (h) Proposed 
model for the mechanism of action of AEZS-136. Activation is represented by continuous black lines, and 
inhibition is represented by dotted gray lines.
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reduced (Fig. 4e), leading to significantly increased cell death (Fig. 4f). Additionally, IER3 silencing was associ-
ated with decreased ERK expression (Supplementary Fig. S10). In keeping with previously reported data showing 
that IER3 and ERK regulate each other’s activities, our data further support that IER3 acts both as an ERK down-
stream effector affecting survival and as a regulator of ERK activation (Fig. 4g)32.
Figure 3. Specific and common biological processes involved in AEZS-136 sensitivity or resistance. 
(a) The enriched biological processes listed in Supplemental Table 2A,B were analyzed using the Cytoscape 
EnrichmentMap plugin and were grouped into two main categories: Cell Death and Cell Cycle. Specific L-540/
SUP-HD1 cell-associated and KM-H2/L-428 cell-associated biological processes are indicated by orange and 
blue nodes, respectively; common processes are indicated by yellow nodes. The light and dark gray edges 
show the interaction between the L-540/SUP-HD1 cell-associated and the KM-H2/L-428 cell-associated 
biological processes, respectively. The node size reflects the number of genes. (b) Heat map of genes listed in 
Supplemental Table 3. Shown are the genes that were differentially expressed in at least three HL cell lines. 
Oppositely modulated gene between the L-540/SUP-HD1 cells and between the KM-H2/L-428 cells is indicated 
by blue rectangle. (c) Western blot analysis of IER3 basal expression in HL cell lines. Equal protein loading was 
confirmed by immunoblotting for β -actin.
www.nature.com/scientificreports/
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Figure 4. IER3-directed siRNA enhances AEZS-136-induced ROS production and cell death. (a) KM-H2 
and L-428 cells were transfected with IER3 siRNA #1 and #2 or control siRNA 1 and #2 and treated with 
AEZS-136 or DMSO vehicle. After 24 hours, the efficiency of IER3-directed siRNA inhibition was analyzed 
via immunofluorescence using an IER3-specific antibody. Cell nuclei (blue) were detected using Hoechst dye. 
Objective lens, 1.0 NA oil objective; original magnification, 60x; zoom, 3x; scale bar, 20 μ m. In the isotype 
control, the cells were incubated with a Goat IgG isotype control (Alexa Fluor 488) (antibodies-online GmbH, 
www.nature.com/scientificreports/
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Effects of AEZS-136 on the growth of HL subcutaneous xenografts. AEZS-136 affected in a 
dose-dependent manner not only the in vivo growth of the AEZS-136-sensitive L-540 xenografts [tumor growth 
inhibition (TGI) = 72% at 60 mg/kg] but also the growth of the AEZS-136-resistant L-428 xenografts (TGI = 60% 
at 60 mg/kg) (Fig. 5a). To understand the unexpected results detected for L-428 xenografts, we first evaluated 
Ki-67 expression and tumor necrosis in both L-540 and L-428 tumor xenografts. Ki-67 expression was strongly 
reduced in both tumor xenografts (Fig. 5b), demonstrating that AEZS-136 inhibited cell proliferation as expected 
based on in vitro data. Tumor necrosis was increased by 10-fold compared with controls (19 ± 2% vs. 1.7 ± 2%, 
P ≤ 0.0001) in L-540 nodules, whereas no evidence of in vivo cytotoxicity could be detected in the AEZS-
136-unresponsive L-428 tumors (Fig. 5c,d), showing that L-428 cells were resistant to AEZS-136-induced cell 
death both in vitro and in vivo.
We then hypothesized that the marked AEZS-136-induced TGI in both L-540 and L-428 xenografts might 
be linked to the inhibition of tumor angiogenesis triggered by activation of the PI3K/AKT and RAS/MEK/
ERK pathways33. AEZS-136 strongly reduced AKT and ERK1/2 phosphorylation in tumor and vascular cells in 
both HL cell lines (Fig. 6a). As compared with controls, both L-540 and L-428 tumors showed vessels smaller in 
length, lacking in sproutings and substantially less arborized and dishomogeneously distributed within the tumor 
(Fig. 6b), suggesting that AEZS-136 affected not only tumor cells but also tumor angiogenesis. Antiangiogenetic 
effects of AEZS-136 might therefore significantly contribute to the in vivo antitumor activity detected in the 
AEZS-136-resistant cell line. Consistent with the in vitro data, we detected marked IER3 downregulation in 
L-540 AEZS-136-treated tumors, whereas we found strong IER3 upregulation in L-428 AEZS-136-treated tum-
ors (Fig. 6c), compared with controls. Taken together, these results suggest that the in vivo antitumor efficacy of 
AEZS-136 is associated with tumor cell death, resulting from decreased IER3 expression in tumor cells.
Discussion
The PI3K/AKT/mTOR and RAS/MEK/ERK pathways are two of the most important signaling cascades that are 
dysregulated by genetic lesions or hyperactivation in the majority of human cancers34. Carracedo and colleagues 
demonstrated the crossover and compensatory mechanisms that exist between these two important pathways35. 
Furthermore, genetic and pharmacological analyses have shown that the RAS/RAF1/MEK1/MEK2 arm of the 
MAPK signaling pathway is responsible for ERK/AKT signaling downstream of S6K1/PI3K when mTORC1 
activity is lost, indicating that targeting the MAPK pathway might improve the efficacy of mTORC1 inhibition36. 
Therefore, the concept of rationally combining molecular targeted therapeutics, to disrupt either a specific path-
way at different levels or two different pathways acting in a complementary manner, has attracted considerable 
interest37.
In this study, we elucidated the molecular mechanism(s) by which the PI3K/ERK dual inhibitor AEZS-136 
exerted a variety of antitumor effects both in vitro and in HL xenografts. These antitumor effects were achieved 
using AEZS-136 concentrations of 10 μ M. While pharmacokinetics data are not available in humans, studies 
in cynomolgus monkeys have shown that a 10 μ M plasma concentration can be reached upon oral AEZS-136 
administration at 90–300 mg/kg (I. Seipelt, Aeterna Zentaris, personal communication). Potent cell death induc-
tion by AEZS-136 was associated with the transcriptional modulation of cell cycle- and cell death-associated 
pathways, ultimately causing caspase-independent necroptotic cell death, which was associated with a striking 
increase in ROS production, with JNK activation, and with mitochondrial injury. These findings were consistent 
with our previous studies demonstrating the synergistic anti-HL activities of sorafenib and perifosine, including 
the inhibition of the MAPK and AKT pathways and the promotion of necroptosis27.
We investigated the mechanism of HL cell resistance to the necroptotic cell death induced by the concomi-
tant PI3K and ERK inhibition. We show that elevated IER3 and phospho-ERK expression were associated with 
decreased ROS levels in the AEZS-136-resistant HL cell lines (i.e., KM-H2 and L-428). The stress-inducible gene 
IER3 was indeed identified as the primary mediator of resistance to AEZS-136-induced oxidative death both in vitro 
and in vivo38. This molecular mechanism is similar to what observed with drug resistance to RAF inhibitors 
which is due to hyperactivation rather than inhibition of the ERK cascade. In fact, non-saturating concentra-
tions of the inhibitor lead to a partial inhibition of the target which in turn results in its strong hyperactivation39. 
IER3 gene play a role in the ERK signaling pathway by inhibiting the dephosphorylation of ERK by phosphatase 
Germany, EU). In the negative control, the IER3 antibody was omitted, and the cells were incubated with 
secondary antibody alone. (b) Cell death after 48 hours was measured as described in the Methods section. 
The mean (±SEM) values correspond to three independent experiments. *P ≤ 0.0001 compared with control 
siRNA. (c) The generation of ROS after 48 hours was measured. *P ≤ 0.0001, #P ≤ 0.001, °P ≤ 0.01 compared 
with control siRNA. (d) Proposed model for ectopic IER3 upregulation: (left panel) AEZS-136 causes IER3 
downregulation in the cell death-sensitive cell lines, leading to necroptotic cell death. (right panel) Lentiviral 
IER3 transduction ectopically increased IER3 expression, preventing AEZS-136-induced necroptotic cell 
death. Activation is represented by continuous lines, and inhibition is represented by dotted lines. (e) KM-H2 
and L-428 cells were transfected with ERK1/2 siRNA or control siRNA and treated with AEZS-136 or DMSO 
vehicle. After 48 hours, the efficiency of ERK1/2-directed siRNA inhibition on IER3 was analyzed via real-time 
RT-PCR. PCR data were normalized to the expression of β 2-microglobulin as a housekeeping gene. (f) Cell 
death after 48 hours was measured as described in the Methods section. The mean (± SEM) values correspond 
to three independent experiments. ***P ≤ 0.0001. (g) Proposed model for the mechanism of IER3 upregulation: 
(left panel) AEZS-136 causes pERK1/2 upregulation in the cell death-resistant cell lines. (right panel) ERK 
siRNA restores AEZS-136-induced necroptotic cell death. Activation is represented by continuous lines, and 
inhibition is represented by dotted lines.
www.nature.com/scientificreports/
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PP2A-PPP2R5C holoenzyme40. Acts also as an ERK downstream effector mediating survival32. As a member 
of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable 
resistance to cell stress, such as starvation or gemcitabine treatment41.
IER3 regulates cell cycle progression, cell proliferation, and cell death42. Additionally, in cells under stress 
IER3 participates in multiple cell signaling pathways, such as ERK signaling prolongation, nuclear Mcl-1 accu-
mulation, and DNA repair32,43. Notably, IER3 depletion using a specific siRNA significantly restored AEZS-
136-induced oxidative cell death in these cell lines, as well as decreased ERK phosphorylation, indicating that the 
activation of this stress-inducible gene played a major role in the mechanism underlying resistance to AEZS-136. 
Novel findings have correlated IER3 overexpression with mitochondrial F1Fo-ATPase inhibitor (IF1) degrada-
tion, increased ATP synthase/ATPase activity and sustained Δ ψ m in a polarized state, thus protecting cells from 
mitochondrion-dependent apoptosis44. By contrast, a lack of IER3 stabilizes IF1 and decreases F1Fo-ATPase 
activity and has been associated with increased ROS production44,45. Thus, we can speculate that IER3 overex-
pression blocks AEZS-136-induced cell death by inhibiting ROS generation and inducing pERK upregulation.
AEZS-136 induced ROS generation and a potent oxidative stress associated with necroptosis46. There are 
many studies that provide evidence for a role of ROS as critical mediators of necroptosis29. Schenk and Fulda 
showed that necroptotic cell death induced by treatment with TNFα and the Smac mimetic BV6 depends on ROS 
as critical regulators of necroptotic signaling and cell death47. Moreover, TNFα -induced ROS generation and 
cytotoxicity were inhibited by a mitochondrial respiratory chain inhibitor but not by a NADPH oxidase inhibitor, 
supporting that mitochondrial rather than cytosolic ROS are involved in mediating TNFα -induced necroptosis48. 
Additional studies on components of the mitochondrial permeability transition (MPT) pore underlined the link 
existing between ROS production and necroptotic cell death. Opening of the MPT pore has been shown to result 
in defective oxidase phosphorylation, generation of ROS and cell death49. The MPT is composed of cyclophilin D 
and genetic evidence derived from cyclophilin D knockout mice underscored the critical role of cyclophilin D in 
Figure 5. Effect of AEZS-136 on tumor growth and tumor necrosis. (a) NOD/SCID mice bearing 100-mm3 
SC tumor nodules were randomly assigned to receive 10-day treatment with AEZS-136 (30 mg/kg, 5 days/
week for 2 weeks, PO, blue or 60 mg/kg, 5 days/week for 2 weeks, PO, red) or vehicle control treatment (black). 
Each experiment was performed on at least two separate occasions using 5 mice per treatment group. For each 
cell line, the treatment duration is indicated by horizontal capped black lines (days 11–21 and days 24–32 for 
the L-540 and L-428 xenografts, respectively). The mean (±SEM) tumor volumes are shown. *P ≤ 0.0001 and 
°P ≤ 0.01 compared with the controls. (b) Ki-67 staining of the L-540 and L-428 tumors treated with AEZS-136 
(60 mg/kg/day, 5 days) or the vehicle control. In the Ki-67-stained section, brown staining represents a positive 
signal within the tumor (the blue cells are Ki-67-negative, living cells). Objective lens, 0.75 NA dry objective; 
original magnification, 20x. Scale bar, 100 μ m. (c) NOD/SCID mice bearing SC tumor nodules (100 mm3) were 
randomly assigned to receive 5 days of treatment with AEZS-136 (60 mg/kg/day, PO) or the vehicle control. 
Representative histological images of entire tumor sections. Tumor tissue morphology was detected via H&E 
staining. The tumor necrotic areas were detected via TUNEL staining and were visualized as brown. Objective 
lens, 0.08 NA dry objective; original magnification, 2x. (d) Digitally acquired TUNEL-stained sections were 
analyzed using ImageJ software for the quantification of the percentage of tumor necrosis. At least three 
sections from different animals were analyzed per treatment group. The boxes extend from the 25th to the 75th 
percentiles, the lines indicate the median values, and the whiskers indicate the range of the values. P ≤ 0.0001 
compared with the controls.
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the regulation of necrotic cell death49. Also, TNFα -induced necroptosis has been reported to be partially reduced 
in mouse embryonic fibroblasts derived from cyclophilin D knockout mice50.
ROS are believed to oxidize MAPK phosphatases (MKPs), the normal function of which is to downregulate 
JNK pathway signaling51, thereby resulting in prolonged JNK activation and cell death. In vitro, AEZS-136 signifi-
cantly increased ROS levels, mitochondrial depolarization, and JNK phosphorylation in AEZS-136-sensitive cells 
but not in AEZS-136-resistant cells. These events were prevented by treatment with the ROS inhibitor YCG063 or 
necrostatin-1, suggesting that ROS production was a prerequisite for AEZS-136-mediated necroptotic cell death 
and strongly supporting the involvement of JNK in AEZS-136-induced cell death. In agreement with previously 
published data52 showing the involvement of JNK in necroptotic cell death, we found that JNK inhibition using 
the JNK inhibitor SP600125 prevented AEZS-136-induced mitochondrial membrane depolarization, ROS gen-
eration, and necroptotic cell death, strongly supporting the reciprocal activation of ROS and JNK via a positive 
feedback loop ultimately causing necroptotic cell death.
Although HL cell lines have been instrumental in identifying genetic lesions and deregulated signaling in HRS 
cells, the differences between these cell lines and primary HRS cells should also be considered when extrapolating 
to patients the results obtained in HL cell lines53. New preclinical models are needed to validate the therapeutic 
potential of AEZS-136. The in vivo xenograft data reported herein suggested that AEZS-136 induced antivascular 
effects and reduction of tumor growth in all HL models. According to our in vitro data, tumor necrosis and IER3 
downregulation were shared only by cell death-sensitive AEZS-136 cells, suggesting a key role of IER3 in AEZS-
136-iduced resistance. Notably, compared with treatment with each agent alone, the combined treatment with 
perifosine and sorafenib induced severe IER3 inhibition in the AEZS-136-responsive HL cells (Supplementary 
Fig. S11). Therefore, it is tempting to speculate that IER3 downregulation correlates with the effectiveness of con-
comitant PI3K and ERK pathway inhibition.
Figure 6. Antivascular activity by AEZS-136 and quantification of IER3 expression in the entire 
tumor sections. (a) Ninety-six hours after treatment with AEZS-136 and 3 hours after the last AEZS-136 
administration, NOD/SCID mice were IV injected with 0.2 ml of sulfo-NHS-LC-biotin (5 mg/ml) to biotinylate 
the tumor vasculature. Tumors were then excised, embedded in cryoembedding compound and freshly snap-
frozen in isopentane. Tumor sections were double-stained with streptavidin (red) and phospho-ERK1/2 
(green) or phospho-AKT (green). Nuclei were detected with Hoechst (blue). Arrows indicate phospho-ERK1/2 
or phospho-AKT expression by endothelial cells; arrowheads indicate phospho-ERK1/2 or phospho-AKT 
expression by tumor cells. Representative images are shown. Objective lens, 1.0 NA oil objective; original 
magnification, 60x. Scale bar, 25 μ m. (b) NOD/SCID mice bearing SC tumor nodules (100 mm3) were randomly 
assigned to receive 5 days of treatment with AEZS-136 (60 mg/kg/day, PO) or the vehicle control. Representative 
histological images of tumors from in vivo biotinylated mice receiving AEZS-136 or vehicle-control are shown. 
Biotinylated endothelia were revealed by sequentially incubating frozen sections with HRP-streptavidin and 3,3′ 
-diaminobenzidine for light microscopy analysis. Objective lens, 0.75 NA dry objective; original magnification, 
20x. Scale bar, 50 μ m. (c) Representative confocal images of tumors from the vehicle-treated and AEZS-136-
treated animals that were processed via double immunofluorescence staining are shown. Cell nuclei (blue) were 
detected using Hoechst dye. IER3 expression (green) was detected using the anti-IER3 antibody and an Alexa 
Fluor 488-conjugated secondary antibody. Cell nuclei (blue) were detected using Hoechst dye. Objective lens, 
1.0 NA oil objective; original magnification, 60x; zoom, 3x.
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Recently, the role of IER3 in patients with myelodysplastic54 and Sézary45 syndromes has been described. 
Mice overexpressing IER3 spontaneously developed T-cell lymphoma, likely due to altered apoptosis sensitivity 
(including susceptibility to death receptor ligation), cell cycle progression, and/or proliferation55. Collectively, 
our data suggested that IER3 expression in tumor samples after AEZS-136 treatment might serve as a biomarker 
of treatment response allowing the identification of AEZS-136 unresponsive patients treatment56. The next step 
would be to understand better the cause of increased IER3 expression in AEZS-136-resistant HL to identify the 
optimal combination therapy, including therapies that would induce apoptosis irrespective of IER3 levels (cispla-
tin, gemcitabine, or doxorubicin) or that would increase ROS levels57. Indeed, we are currently investigating this 
potential strategy to restore the efficacy of AEZS-136 therapy in HL cells displaying increased IER3 expression.
In conclusion, our data suggested that AEZS-136 might be clinically effective for HL and other hematological 
malignancies characterized by PI3K and ERK phosphorylation. Our findings could have significant implications 
for the clinical development of AEZS-136.
Methods
Reagents. AEZS-136 was provided by Æterna Zentaris (Frankfurt, Germany, EU). Z-VAD-FMK and necrostatin-1 
(R&D Systems, Minneapolis, MN, USA). Tetramethylrhodamine ethyl ester (TMRE) and 6-carboxy-2′ ,7′ -dichlo-
rodihydrofluorescein diacetate di(acetoxymethyl ester) (H2DCFDA) (Invitrogen, Milan, Italy, EU). YCG063 
and SP600125 (Merck Millipore, Billerica, MA, USA). Stock solutions of each reagent were prepared in 100% 
dimethylsulfoxide (DMSO) and subsequently a working solution was obtained by diluting (at least 1:1000, v/v) 
in RPMI.
Cell lines. The L-540, SUP-HD1, KM-H2 and L-428 cell lines were purchased from the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany, EU). Cell lines were cultured in RPMI-1640 
supplemented with 20% fetal bovine serum (FBS). The identity of the cell lines was authenticated by multiplex 
PCR of minisatellite markers that revealed a unique DNA profile. Cell cultures were also tested for the presence of 
Mycoplasma (Mycoplasma Detection Kit, Invivogen) before the initiation of this study.
Cell proliferation assay. Cell proliferation was evaluated by Quick Cell Proliferation Assay Kit II (BioVision 
Research Products, CA, USA), following the manufacturer’s instructions. Cell proliferation inhibition rate was 
calculated as the percentage of proliferation reduction in comparison to the proliferation of vehicle-controls.
Cell death assay. Dead cells (Annexin-V+ /PI+ and Annexin-V-/PI+ cells) were detected via Annexin-V/PI 
double-staining and flow cytometry58. Cells were analyzed using a FACSCalibur flow cytometry system 
(Becton-Dickinson, San Jose, CA, USA). The data were analyzed using FlowJo software (Tree Star, Inc., Ashland, 
OR, USA), version 8.7.1.
Cell cycle analysis. The cells were cultured under the appropriate conditions for 48 hours, fixed in 70% eth-
anol, and stained with 2.5 μ g/ml PI (Calbiochem, Darmstadt, Germany). Cell cycle status was measured using a 
FACSCalibur flow cytometry system (BD) and was analyzed using FlowJo software.
Western blot analysis. Western blot analysis was performed using antibodies against Mcl-1, JNK (56G8), 
pJNK (81E11), pMEK (41G9), MEK (D1A4), pERK1/2 (197G2), ERK1/2 (137F5), pAKT (S473) (193H12), pAKT 
(T308) (244F9), AKT, pS6 (Ser235/236), S6, p4EBP-1 (Thr70), 4EBP-1, pPI3K p85 (Tyr458)/p55(Tyr199) (Cell 
Signaling Technology, Danvers, MA, USA), PI3K p110 delta (Novus Biologicals), caspase-3, p21, IER3 (Santa 
Cruz Biotechnologies, San Diego, CA, USA), and poly(ADP-ribose) polymerase (PARP) (BD).
Measurement of the mitochondrial membrane potential (ΔΨm). Mitochondrial membrane depo-
larization was determined using the fluorescent probe TMRE (Invitrogen) and was analyzed by flow cytometry.
Measurement of ROS. ROS generation was detected as previously described22. An Olympus IX81 confocal 
microscope and an Olympus oil immersion objective lens (40x/1.3 Plan-Apochromat) (Olympus, Milan, Italy, 
EU) were used. The images were acquired (1 frame every 30 seconds, 140 frames total) and processed using 
Xcellence software (Olympus).
Genome-wide expression profiling. The cells were treated with AEZS-136 (10 μ M) for 2 or 24 hours. 
RNA integrity and the purity of the treated cells were assessed using a Bioanalyzer (Agilent Technologies, Milan, 
Italy, EU). Hybridization to an Illumina Microarray (Illumina, San Diego, CA, USA) was performed. The gene 
expression data are available in the NCBI Gene Expression Omnibus database (accession numbers GSE71150 and 
GSE58899). Robust spline normalization and L2T were performed in R software, using the lumi package from 
Bioconductor open source software (http://www.bioconductor.org/). The significantly differentially expressed 
genes were identified using Student’s t-test adjusted according to the Benjamini-Hochberg (bh) procedure by 
considering account transcripts displaying Padj < 0.05. Furthermore, transcripts displaying a log2 fold-change 
in expression of > − 0.4 or < 0.4 were filtered out. One-way hierarchical clustering of the significantly modulated 
genes was performed on the gene-wise median-centered normalized intensities, using Cluster software, version 
3.0. Centered correlation and complete linkage clustering were used as the distance metrics. Heat maps were 
visualized using Java Treeview software. Functional annotation of the significantly differentially expressed genes 
identified, based on microarray analysis, was performed using DAVID Bioinformatics Resources (david.abcc.
ncifcrf.gov). Cytoscape software, version 2.8 (http://www.cytoscape.org/), and the EnrichmentMap plugin were 
used to perform network analysis.
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Quantitative real-time PCR (qRT-PCR). mRNA isolation, cDNA reverse transcription, and qRT-PCR were 
performed as described previously27. qRT-PCR was performed using TaqMan gene expression assays for DCTPP1 
(Hs00225433_m1), HNRNPAB (Hs00954054_g1), CCNA2 (Hs00996788_m1), MAPK3 (Hs00385077_m1) 
and IER3 (Hs04187506_g1) (Applied Biosystems, Foster City, CA, USA) and an ABI ViiA7 sequence detec-
tion system (Applied Biosystems). The data were normalized to the expression levels of the housekeeping gene 
β 2-microglobulin.
siRNA-mediated gene silencing. KM-H2 and L-428 cells were transfected with 100 nM of either 
Silencer Select IER3-directed small interference RNA (siRNA) or Silencer Select Negative Control siRNA 
(Ambion, Carlsbad, CA, USA); SignalSilence p44/42 MAPK (ERK1/2) siRNA or Control siRNA (Cell Signaling 
Technology) according to the manufacturer’s instructions. Twenty-four hours after transfection, the cells were 
treated with 10 μ M AEZS-136. The effects of gene silencing were evaluated by immunofluorescence, mRNA and 
cell death as described above after 24 and 48 hours of drug exposure.
Lentiviral transduction. Lentiviral vectors including a lentivirus empty cassette (LV-Scrambled) and a 
lentivirus encoding the human IER3 gene (LV-IER3) were purchased from (Cellomics Technology, MD, USA). 
Transduction was performed in 48-well plates. L-540 was seeded at (0.4 × 106 cells/ml), 105 cells per well. One day 
later, the cells were transduced with a final multiplicity of infection (MOI) of 20 (PFU)/cell of both LV-Scrambled 
and LV-IER3 for 24 hrs. Six days after transduction, the efficiency was measured by detecting IER3 using immu-
nofluorescence analysis.
Activity of AEZS-136 in tumor-bearing non-obese, diabetic/severe combined immunodeficient 
(NOD/SCID) mice. Six- to eight-week-old NOD/SCID mice with body weights of 20–25 g were purchased 
from Charles River (Milan, Italy, EU) and were xenografted with L-540 or L-428 cells. Animal experiments were 
performed according to EU 86/109 Directive (D.L. 116/92 and following additions) and approved by the institu-
tional Ethical Committee for Animal Experimentation of the Humanitas Clinical and Research Center. The activity 
of AEZS-136 was analyzed in the subcutaneous (SC) xenograft models. L-540 (25 × 106 cells/mouse) or L-428 
(20 × 106 cells/mouse) cells were inoculated into the left flank of each mouse. When the tumor volume reached 
approximately 100 mm3, mice were randomly assigned to receive either short- or long-term treatment with 
AEZS-136 [working solution containing 10% DMSO (v/v)] or vehicle [10% DMSO solution (v/v)]. As previously 
reported26, mice treatment with a 10% DMSO solution failed to affect tumor cell signaling likely due to in vivo  
dilution of DMSO as well as its rapid metabolic clearance. The short-term treatment consisted of AEZS-136 
(60 mg/kg/5 days, PO) and was used to assess necrotic areas and tumor cell proliferation. In vivo biotinylation of 
tumor vasculature was performed when appropriate 3 hours after the last AEZS-136 administration. Tumor nod-
ules were then excised and processed for histological analysis. The long-term treatment consisted of AEZS-136 
(30 or 60 mg/kg/5 days for 2 wks, PO). The tumor volumes were calculated using the following formula: (a × b2)/2, 
where a and b represent the longest and shortest diameters, respectively. Tumor growth inhibition (TGI) was defined 
as (1 − [T/C] × 100), where T and C represent the mean tumor volumes in the treated and untreated control groups, 
respectively. Each experiment was performed on at least two separate occasions using five mice per treatment group.
Immunofluorescence and confocal microscopy. Cells were cytospun onto positively charged glass slides, 
fixed with cold acetone, and blocked with 2% BSA. Otherwise, epitope retrieval was performed on formalin-fixed, 
paraffin-embedded (FFPE) nodules using EDTA buffer. The samples were incubated in a goat anti-human 
IER3 (1:50) (Santa Cruz Biotechnology, Heidelberg, Germany, EU), -pAKT (S473), -pERK1/2 and -pS6 (Cell 
Signaling Technology, Leiden, The Netherlands, EU) antibodies, followed by the appropriate Alexa Fluor 488- and 
568-conjugated secondary antibody (Invitrogen). Cryostat sections (4-μ m thick) of in vivo biotinylated tumor 
nodules were double-stained with Alexa Fluor 568-streptavidin (Invitrogen) and anti-human phospho-AKT 
(Ser473) or phospho-ERK1/2 (Cell Signaling). Tumor/endothelial p-AKT or p-ERK1/2 expression was revealed 
by Alexa Fluor 488-conjugated secondary antibody (Invitrogen). Finally, the sections were labeled with Hoechst 
nuclear dye (1:10,000) (Invitrogen) and examined under a confocal microscope (Nikon A1R, Nikon Instruments, 
Florence, Italy, EU). Image processing was performed using NIS-Elements AR software (Nikon Instruments).
Histological analysis and immunohistochemistry. Sections (2-μ m thick) from FFPE human tumor 
xenografts and lymph node biopsies obtained from consenting patients at the time of diagnostic work-up 
were stained with hematoxylin and eosin (H&E) or with anti-human Ki-67 antibody (Dako, Milan, Italy, EU), 
-pAKT (S473), -pAKT (T308), -pERK1/2 or -pS6 (Cell Signaling) antibodies. Chemosensitive and chemorefrac-
tory patients were defined according to the criteria of German Hodgkin Lymphoma Study Group59. Study was 
approved by the by the institutional Ethical Committee of the Humanitas Clinical and Research Center. Tumor 
necrosis was detected via TUNEL staining (Roche, Milan, Italy, EU). Cryostat sections (4-μ m thick) of in vivo 
biotinylated tumor nodules were processed as previously described28. The sections were examined under a light 
microscope (IX51; Olympus, Tokyo, Japan). Image analysis was performed using ImageJ software60.
Statistical analyses. Statistical analysis was performed using Prism 6 software (GraphPad Software, inc., La 
Jolla, CA, USA) and a Macintosh Pro personal computer (Apple Computer). To test the probability of significant 
differences between the untreated and treated samples, two-way analysis of variance (ANOVA) was used, and 
individual group comparisons were evaluated using Bonferroni’s test. The TUNEL staining data were analyzed 
via one-way analysis of variance (ANOVA), and individual group comparisons were evaluated using Bonferroni’s 
test. The differences were considered significant at P ≤ 0.05.
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